Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.68 |
| ▸ | GSK3B | P49841 | 9/20 | 0.68 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14427364 | 0.90 | CDK2 (0.56) | CDK2GSK3BCDK1CDK9CCNB2 | |
| SCHEMBL13985880 | 0.89 | CDK2 (0.56) | CDK2GSK3BCDK9CCNE1KDM4E | |
| SCHEMBL12143269 | 0.88 | CDK2 (0.70) | CDK2GSK3BCDK1CDK9 | |
| SCHEMBL14427421 | 0.86 | CDK2 (0.55) | CDK2GSK3BCDK9KDM4EMEN1 | |
| SCHEMBL5448114 | 0.86 | CDK2 (0.52) | CDK2GSK3BCDK1CDK9CCNB1 | |
| SCHEMBL14427360 | 0.86 | CDK2 (0.52) | CDK2GSK3BCCNE1MAPT | |
| SCHEMBL14427390 | 0.85 | CDK2 (0.67) | CDK2GSK3BCDK1CDK9CCNB1 | |
| SCHEMBL13885062 | 0.84 | GSK3B (0.71) | CDK2GSK3BCDK1CDK9CCNB2 | |
| SCHEMBL14427377 | 0.84 | GSK3B (0.54) | CDK2GSK3BCDK1CDK9CCNB2 | |
| SCHEMBL14427370 | 0.84 | CDK2 (0.53) | CDK2GSK3BCDK9KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179161-A1 | Pyrazolopyrimidine compounds and their use in medicine | VERNALIS (CAMBRIDGE) LIMITED. (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179161-A1 | Pyrazolopyrimidine compounds and their use in medicine | VERNALIS (CAMBRIDGE) LIMITED. (GB) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179161-A1 | Pyrazolopyrimidine compounds and their use in medicine | ROS1, ALK, NOX1 | CDK2 228/4885GSK3B 409/4885CDK1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.